A citation-based method for searching scientific literature

Bogyeong Han, Sehui Kim, Jiwon Koh, Jeemin Yim, Cheol Lee, Dae Seog Heo, Tae Min Kim, Jin Ho Paik, Yoon Kyung Jeon. Cancers (Basel) 2020
Times Cited: 3







List of co-cited articles
13 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
482
100




Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Alex F Herrera, Matthew Mei, Lawrence Low, Haesook T Kim, Gabriel K Griffin, Joo Y Song, Reid W Merryman, Victoria Bedell, Christine Pak, Heather Sun,[...]. J Clin Oncol 2017
113
66

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.
Laura K Hilton, Jeffrey Tang, Susana Ben-Neriah, Miguel Alcaide, Aixiang Jiang, Bruno M Grande, Christopher K Rushton, Merrill Boyle, Barbara Meissner, David W Scott,[...]. Blood 2019
45
66

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
661
66

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.
Brett Collinge, Susana Ben-Neriah, Lauren Chong, Merrill Boyle, Aixiang Jiang, Tomoko Miyata-Takata, Pedro Farinha, Jeffrey W Craig, Graham W Slack, Daisuke Ennishi,[...]. Blood 2021
14
66

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.
T Petrella, C Copie-Bergman, J Brière, R Delarue, F Jardin, P Ruminy, C Thieblemont, M Figeac, D Canioni, P Feugier,[...]. Ann Oncol 2017
19
66

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
David W Scott, Rebecca L King, Annette M Staiger, Susana Ben-Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W Slack, Daisuke Ennishi,[...]. Blood 2018
109
66

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
66


Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
717
66

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
Chulin Sha, Sharon Barrans, Francesco Cucco, Michael A Bentley, Matthew A Care, Thomas Cummin, Hannah Kennedy, Joe S Thompson, Rahman Uddin, Lisa Worrillow,[...]. J Clin Oncol 2019
106
33

A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies.
Carsten Bahr, Lisa von Paleske, Veli V Uslu, Silvia Remeseiro, Naoya Takayama, Stanley W Ng, Alex Murison, Katja Langenfeld, Massimo Petretich, Roberta Scognamiglio,[...]. Nature 2018
155
33

R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
Jonathan W Friedberg, Joseph M Unger, W Richard Burack, Ajay K Gopal, Robert N Raju, Auayporn P Nademanee, Mark S Kaminski, Hongli Li, Oliver W Press, Thomas P Miller,[...]. Br J Haematol 2014
25
33

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
Marita Ziepert, Dirk Hasenclever, Evelyn Kuhnt, Bertram Glass, Norbert Schmitz, Michael Pfreundschuh, Markus Loeffler. J Clin Oncol 2010
391
33

Characterisation of immunogenotypes of diffuse large B-cell lymphoma.
K C Phang, N H Hussin, F Abdul Rahman, N M S Tizen, A Mansoor, N Masir. Malays J Pathol 2019
3
33

A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.
Marita Ziepert, Stefano Lazzi, Raffaella Santi, Federica Vergoni, Massimo Granai, Virginia Mancini, Annette Staiger, Heike Horn, Markus Löffler, Viola Pöschel,[...]. Haematologica 2020
4
33

Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India.
Babu Suresh, Vikas Asati, K C Lakshmaiah, Govind Babu, D Lokanatha, Linu Abraham Jacob, K N Lokesh, A H Rudresh, L K Rajeev, Saldanha Smitha,[...]. South Asian J Cancer 2019
7
33

Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
Linyu Li, Xuhan Zhang, Tingting Zhang, Zheng Song, Ge Hu, Wei Li, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou,[...]. Clin Lymphoma Myeloma Leuk 2018
10
33

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Qing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, Lijuan Deng, Xiaoxiao Wang, Ganiraju C Manyam, Carlo Visco, Santiago Montes-Moreno, Li Zhang, Karen Dybkær,[...]. Oncotarget 2016
70
33

Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation.
Margit Schraders, Daphne de Jong, Philip Kluin, Patricia Groenen, Han van Krieken. J Pathol 2005
67
33

MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
Li-Xu Yan, Yan-Hui Liu, Dong-Lan Luo, Fen Zhang, Yu Cheng, Xin-Lan Luo, Jie Xu, Jie Cheng, Heng-Guo Zhuang. PLoS One 2014
32
33

Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.
Seung Woo Cho, Jin Xu, Ruping Sun, Maxwell R Mumbach, Ava C Carter, Y Grace Chen, Kathryn E Yost, Jeewon Kim, Jing He, Stephanie A Nevins,[...]. Cell 2018
232
33

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.
Naoto Tomita, Mami Tokunaka, Naoya Nakamura, Kengo Takeuchi, Junki Koike, Shigeki Motomura, Ko Miyamoto, Ako Kikuchi, Rie Hyo, Yoshihiro Yakushijin,[...]. Haematologica 2009
159
33

Aggressive lymphomas.
Georg Lenz, Louis M Staudt. N Engl J Med 2010
426
33

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma.
YunXiang Zhang, Hui Wang, Cuiai Ren, Hai Yu, Wenjia Fang, Na Zhang, Sumei Gao, Qian Hou. Front Pharmacol 2019
9
33


Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.
Mingyang Li, Yixiong Liu, Yingmei Wang, Gang Chen, Qiongrong Chen, Hualiang Xiao, Fang Liu, Chubo Qi, Zhou Yu, Xia Li,[...]. Am J Surg Pathol 2017
17
33

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Anamarija M Perry, Yuridia Alvarado-Bernal, Javier A Laurini, Lynette M Smith, Graham W Slack, King L Tan, Laurie H Sehn, Kai Fu, Patricia Aoun, Timothy C Greiner,[...]. Br J Haematol 2014
131
33


Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma.
Jing Wang, Min Zhou, Jing-Yan Xu, Bing Chen, Jian Ouyang. Onco Targets Ther 2015
8
33

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
Pekka Peroja, Mette Pedersen, Tuomo Mantere, Peter Nørgaard, Jenni Peltonen, Kirsi-Maria Haapasaari, Jan Böhm, Esa Jantunen, Taina Turpeenniemi-Hujanen, Katrin Rapakko,[...]. Sci Rep 2018
14
33

Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Bing Xia, Le Zhang, Shan-Qi Guo, Xiao-Wu Li, Fu-Lian Qu, Hai-Feng Zhao, Lian-Yu Zhang, Bao-Cun Sun, James You, Yi-Zhuo Zhang. World J Gastroenterol 2015
11
33

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
33

The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Hajnalka Rajnai, Fenna H Heyning, Lianne Koens, Anna Sebestyén, Hajnalka Andrikovics, Pancras C W Hogendoorn, András Matolcsy, Ágota Szepesi. Virchows Arch 2014
17
33

Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis.
Jue Jiang, Jingchao Wang, Ming Yue, Xiaolian Cai, Tianci Wang, Chao Wu, Hexiu Su, Yanwu Wang, Meng Han, Yingchi Zhang,[...]. Cancer Cell 2020
30
33

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
Shaoying Li, Adam C Seegmiller, Pei Lin, Xuan J Wang, Roberto N Miranda, Sharathkumar Bhagavathi, L Jeffrey Medeiros. Mod Pathol 2015
56
33

B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Peng-Peng Xu, Hui-Juan Zhong, Yao-Hui Huang, Xiao-Dong Gao, Xia Zhao, Yang Shen, Shu Cheng, Jin-Yan Huang, Sai-Juan Chen, Li Wang,[...]. EBioMedicine 2017
12
33

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris van Vliet, Pedro Farinha, Clare Gould, Simone Birch, Laurie H Sehn, Vishakha Sovani,[...]. Blood Adv 2019
26
33

P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Xuan J Wang, L Jeffrey Medeiros, Carlos E Bueso-Ramos, Guilin Tang, Sa Wang, Yasuhiro Oki, Parth Desai, Joseph D Khoury, Roberto N Miranda, Zhenya Tang,[...]. Mod Pathol 2017
51
33

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
Mark Bosch, Ariz Akhter, Bingshu E Chen, Adnan Mansoor, David Lebrun, David Good, Michael Crump, Lois Shepherd, David W Scott, Douglas A Stewart. Haematologica 2018
11
33

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel,[...]. J Clin Oncol 2017
139
33

Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant.
Joshua Allen, Ana Lucia Ruano Mendez, Lisa Rybicki, Yazeed Sawalha, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Mitchell R Smith, Eric D Hsi, Brian T Hill. Ther Adv Hematol 2018
3
33

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
David W Scott, Anja Mottok, Daisuke Ennishi, George W Wright, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S Barry, Christoffer Hother, Pau Abrisqueta,[...]. J Clin Oncol 2015
239
33

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.
Jonathan Wawire, Shahin Sayed, Zahir Moloo, Aliyah R Sohani. J Glob Oncol 2019
3
33

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis.
Lu Li, Yanyan Li, Ximei Que, Xue Gao, Qian Gao, Mingxing Yu, Kaili Ma, Yanfeng Xi, Tong Wang. Sci Rep 2018
21
33

Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Zhiping Ma, Jing Niu, Yanzhen Cao, Xuelian Pang, Wenli Cui, Wei Zhang, Xinxia Li. J Clin Pathol 2020
8
33

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Magdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang,[...]. Blood 2019
60
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.